503B Outsourcing Facility

Deep dive

503B Outsourcing Facility: complete reference

A 503B outsourcing facility (named for Section 503B of the FD&C Act, added by the 2013 Drug Quality and Security Act) is a compounding entity that voluntarily registers with the FDA to produce larger batches of compounded medications without requiring individual patient prescriptions. Unlike 503A pharmacies (state-regulated, per-patient), 503B facilities are FDA-registered + inspected, subject to current Good Manufacturing Practice (cGMP) standards similar to commercial pharmaceutical manufacturers. They primarily supply hospitals, clinics, surgery centers, and physician offices with sterile compounded products. The FDA maintains a public list of registered 503B facilities. For GLP-1 medications, 503B facilities were a smaller share of compounded volume during the shortage era (most compounded GLP-1s came from 503A pharmacies via telehealth). 503B facilities have higher overhead but stricter quality oversight — useful for institutional purchasers who need volume + verified quality. Post-shortage-resolution, 503B facilities also face narrowed legal grounds for ongoing GLP-1 compounding.

In practice

A 503B facility might supply a hospital pharmacy with pre-prepared injectable solutions for OR use — they're manufacturing under FDA oversight, just not for FDA-approved finished products.

Clinical context

503B = higher quality oversight than 503A but more expensive. Most retail compounded GLP-1 went through 503A pharmacies.